Posted on 10 August 2015
An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.
Tags: big biotech, big pharma, biotech, partnering, pharma
Posted on 07 May 2015
MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
Tags: compound, MorphoSys
Posted on 05 May 2015
Alexion Pharmaceuticals have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015.
Tags: Alexion, rare diseases
Posted on 28 April 2015
Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel
Tags: big biotech, big pharma, Celgene, M&A
Posted on 20 April 2015
Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100
Tags: big biotech, big pharma, partnering
Posted on 14 April 2015
Mesoblast has entered into an Agreement with Celgene
Tags: big biotech, Celgene, financing
Posted on 27 March 2015
MorphoSys has regained rights to MOR202 from Celgene
Tags: big biotech, big biotech company, big pharma, partnering, termination
Posted on 12 March 2015
Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics
Tags: biotech, Celgene, partnering
Posted on 12 March 2015
MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders
Tags: big pharma, Medimmune, partnering
Posted on 04 March 2015
Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates
Tags: biotech, partnering, pharma